According to lead author Dr. Robert Stamper, Professor at UCSF, “The analysis confirms cyclodialysis as an effective procedure for enhancing uveoscleral outflow, with modern ab-interno approaches ...
WHITE PLAINS, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a leader in bio-interventional ophthalmic surgery (BIOS), today announced it has surpassed 2,000 AlloFlo™ Uveo procedures in the U.S ...
New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathway WHITE PLAINS, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer in ...
Please provide your email address to receive an email when new articles are posted on . The treatment enhances aqueous outflow through the uveoscleral pathway. A $42 million Series C financing round ...
AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patients With over 100 surgeon partners and thousands of cases performed throughout the early-release program, Iantrek pioneers a ...
Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, I. Paul Singh, MD, discusses the ...
Iantrek Inc. reported the close of a $42 million series C financing round, which it said will facilitate the U.S. commercial launch of its Alloflo Uveo, a bio-interventional ophthalmic surgery ...
Earlier this year, Iantrek reported that its AlloFlo Uveo system has already been used in more than 2,000 U.S. procedures, ahead of a full commercial launch planned for this fall and into next year.
WHITE PLAINS, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C financing round, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results